Hengrui, BeyondSpring In Arbitration Face-Off After Cancer Deal Setbacks

A Chinese court decision sheds light on how Chinese major Hengrui Medicine is seeking to reduce or avoid potential losses worth up to $27m following regulatory setbacks with the tubulin inhibitor plinabulin, in-licensed from BeyondSpring in 2021.

Jiangsu Hengrui Medicine Co., Ltd. is apparently going all-in to salvage a CNY200m ($27m) upfront payment it made to Dalian Wanchunbulin Pharmaceuticals, a China-based subsidiary of BeyondSpring Inc., in a licensing deal for an oncology product sealed in 2021.

Earlier this year, the two companies went to arbitration at the China International Economic and Trade Arbitration Commission (CIETAC), according...

More from China

More from Focus On Asia